Report
FREE
• Organto has provided several positive updates over the last few months, including the appointment of industry veteran Chad Hagen to its board, the early exercise of its warrants, and a recap of its 2025 achievements.
• OGO will be reporting Q4 and 2025 financial results in late April. For Q4, we are expecting $14.2M in sales (+190% YoY) and $0.2M in EBITDA. For 2025, we are expecting $60.1M (+120% YoY) and ($0.8M) in EBITDA.
• We have introduced our quarterly estimates for 2026.
This morning, Organto Foods (OGO:TSXV, OGOFF:OTC) announced the appointment of Chad Hagen to its board of directors. OGO has also provided several other positive developments since our last note (read here), which we would like to highlight. Q4 financials are expected at the end of April and are expected to be another strong catalyst for the stock, which is up 55% over the last six months. We are maintaining our BUY rating and $1.00/share target price on OGO.
Recent Updates
OGO has announced the appointment of Chad Hagen to its Board of Directors, effective immediately as of today. Replacing Alejandro Maldonado, who resigned on January 26th. Hagen brings more than 30 years of experience in the global natural and organic food and beverage sector, including senior roles at SunOpta and his current position as CCO at Sojo Industries, strengthening Organto’s strategic and commercial expertise as the Company grows.
Throughout the month of January, Organto announced and subsequently received TSXV approval for an early exercise incentive program for 8.0M warrants from its September 2025 private placement. Warrant holders who exercise within 30 days will receive one additional warrant for every three warrants exercised, with incentive warrants exercisable at $1.00 for one year. If fully exercised, the program will generate $6.0M in proceeds and result in the issuance of 2.67M incentive warrants. The Company also disclosed recent equity issuances, including 1.48M shares issued to settle management and employee bonuses, RSU conversions, and stock option exercises from late 2025.
OGO: Couple Solid Updates & Q4 Financials Preview
What you need to know:• Organto has provided several positive updates over the last few months, including the appointment of industry veteran Chad Hagen to its board, the early exercise of its warrants, and a recap of its 2025 achievements.
• OGO will be reporting Q4 and 2025 financial results in late April. For Q4, we are expecting $14.2M in sales (+190% YoY) and $0.2M in EBITDA. For 2025, we are expecting $60.1M (+120% YoY) and ($0.8M) in EBITDA.
• We have introduced our quarterly estimates for 2026.
This morning, Organto Foods (OGO:TSXV, OGOFF:OTC) announced the appointment of Chad Hagen to its board of directors. OGO has also provided several other positive developments since our last note (read here), which we would like to highlight. Q4 financials are expected at the end of April and are expected to be another strong catalyst for the stock, which is up 55% over the last six months. We are maintaining our BUY rating and $1.00/share target price on OGO.
Recent Updates
OGO has announced the appointment of Chad Hagen to its Board of Directors, effective immediately as of today. Replacing Alejandro Maldonado, who resigned on January 26th. Hagen brings more than 30 years of experience in the global natural and organic food and beverage sector, including senior roles at SunOpta and his current position as CCO at Sojo Industries, strengthening Organto’s strategic and commercial expertise as the Company grows.
Throughout the month of January, Organto announced and subsequently received TSXV approval for an early exercise incentive program for 8.0M warrants from its September 2025 private placement. Warrant holders who exercise within 30 days will receive one additional warrant for every three warrants exercised, with incentive warrants exercisable at $1.00 for one year. If fully exercised, the program will generate $6.0M in proceeds and result in the issuance of 2.67M incentive warrants. The Company also disclosed recent equity issuances, including 1.48M shares issued to settle management and employee bonuses, RSU conversions, and stock option exercises from late 2025.
Underlying
Organto Foods Inc
Provider
Atrium Research Corporation
Atrium Research provides institutional quality issuer paid research on North American public equities using deep fundamental analysis. Our research reports are disseminated through Bloomberg, FactSet, Capital IQ, Reuters and many more, as well as through our social media and email distribution lists.
Nicholas Cortellucci, CFA
Other Reports on these Companies
Other Reports from Atrium Research Corporation
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.